JAZZ Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.20%

Insider Buying (Last 12 Months): $1,435,800.00

Insider Selling (Last 12 Months): $1,000,050.92

Jazz Pharmaceuticals Insider Trading History Chart

Jazz Pharmaceuticals Share Price & Price History

^$110.22

▲ +0.65 (0.59%)

As of 09/17/2024 12:47 PM ET

Days: 30 | 90 | 365

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

Jazz Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/6/2024	Mary Elizabeth Henderson	SVP	Sell	1,410	$108.30	$152,703.00	14,531
6/7/2024	Patricia Carr	CAO	Sell	163	$108.83	$17,739.29	6,596
5/3/2024	Neena M. Patil	EVP	Sell	5,000	$109.65	$548,250.00	36,629
3/6/2024	Patricia Carr	CAO	Sell	1,936	$119.64	$231,623.04	8,364
3/1/2024	Philip L. Johnson	CFO	Buy	12,000	$119.65	$1,435,800.00	27,932
12/4/2023	Mark Douglas Smith	Director	Sell	417	$119.27	$49,735.59	6,888
9/1/2023	Neena M. Patil	EVP	Sell	1,500	$144.25	$216,375.00	29,186
8/29/2023	Patricia Carr	CAO	Sell	142	$143.47	$20,372.74	5,986
8/15/2023	Neena M. Patil	EVP	Sell	750	$139.59	$104,692.50	30,686
8/14/2023	Patricia Carr	CAO	Sell	158	$138.16	$21,829.28	6,128
8/14/2023	Rick E. Winningham	Director	Sell	1,241	$138.16	$171,456.56	10,444
6/7/2023	Patricia Carr	CAO	Sell	126	$127.92	$16,117.92	6,286
6/1/2023	Neena M. Patil	EVP	Sell	1,600	$127.98	$204,768.00	32,826
5/18/2023	Renée D. Galá	CFO	Sell	6,000	$131.75	$790,500.00	35,978
3/15/2023	Patricia Carr	CAO	Sell	1,023	$133.22	$136,284.06	6,286
3/8/2023	Kim Sablich	EVP	Sell	3,013	$139.74	$421,036.62	30,560
3/7/2023	Kenneth W. O'Keefe	Director	Sell	2,690	$138.39	$372,269.10	22,889
3/6/2023	Finbar Larkin	SVP	Sell	1,706	$143.92	$245,527.52	23,854
3/5/2023	Patricia Carr	CAO	Sell	1,148	$140.76	$161,592.48	7,309
2/1/2023	Bruce C. Cozadd	CEO	Sell	1,000	$155.79	$155,790.00	367,078
1/3/2023	Bruce C. Cozadd	CEO	Sell	3,000	$159.86	$479,580.00	368,078
1/3/2023	Samantha Pearce	SVP	Sell	531	$159.59	$84,742.29	11,309
12/21/2022	Renée D. Galá	CFO	Sell	2,635	$160.00	$421,600.00	32,558
12/13/2022	Samantha Pearce	SVP	Sell	531	$155.45	$82,543.95	11,309
12/9/2022	Robert Iannone	EVP	Sell	1,844	$151.54	$279,439.76	36,316
12/5/2022	Patricia Carr	CAO	Sell	63	$152.06	$9,579.78	5,934
12/2/2022	Jennifer E. Cook	Director	Sell	420	$154.68	$64,965.60	5,471
12/1/2022	Bruce C. Cozadd	CEO	Sell	1,000	$157.00	$157,000.00	371,078
11/22/2022	Patrick G. Enright	Director	Sell	4,974	$149.48	$743,513.52	19,112
11/14/2022	Finbar Larkin	SVP	Sell	197	$149.33	$29,418.01	19,409
11/10/2022	Bruce C. Cozadd	CEO	Sell	2,000	$150.00	$300,000.00	372,028
11/10/2022	Samantha Pearce	SVP	Sell	1,063	$155.00	$164,765.00	11,309
10/3/2022	Bruce C. Cozadd	CEO	Sell	45,185	$134.93	$6,096,812.05	374,028
9/7/2022	Finbar Larkin	SVP	Sell	63	$150.00	$9,450.00	19,606
9/6/2022	Bruce C. Cozadd	CEO	Sell	7,703	$153.18	$1,179,945.54	353,311
8/18/2022	Peter Gray	Director	Sell	8,000	$158.00	$1,264,000.00	14,234
8/15/2022	Patricia Carr	CAO	Sell	2,142	$160.06	$342,848.52	5,934
8/4/2022	Samantha Pearce	SVP	Sell	531	$155.00	$82,305.00	11,309
8/1/2022	Bruce C. Cozadd	CEO	Sell	7,301	$154.31	$1,126,617.31	354,311
7/12/2022	Samantha Pearce	SVP	Sell	532	$155.00	$82,460.00	11,309
7/5/2022	Bruce C. Cozadd	CEO	Sell	8,775	$157.28	$1,380,132.00	351,912
7/5/2022	Christopher J. Tovey	COO	Sell	5,209	$160.00	$833,440.00	14,663
6/27/2022	Samantha Pearce	SVP	Sell	8,508	$155.00	$1,318,740.00	11,309
6/8/2022	Samantha Pearce	SVP	Sell	8,487	$155.00	$1,315,485.00	11,309
6/6/2022	Kim Sablich	EVP	Sell	1,388	$152.15	$211,184.20	27,195
6/6/2022	Neena M. Patil	Insider	Sell	1,000	$152.15	$152,150.00	31,600
6/1/2022	Bruce C. Cozadd	CEO	Sell	6,362	$146.87	$934,386.94	351,987
5/11/2022	Patricia Carr	CAO	Sell	722	$147.51	$106,502.22	6,234
5/9/2022	Anne Oriordan	Director	Sell	466	$148.95	$69,410.70	9,245
5/9/2022	Finbar Larkin	SVP	Sell	1,747	$148.94	$260,198.18	19,462
5/9/2022	Patricia Carr	CAO	Sell	1,067	$148.94	$158,918.98	7,229
5/6/2022	Neena M. Patil	Insider	Sell	296	$153.92	$45,560.32	32,677
5/2/2022	Bruce C. Cozadd	CEO	Sell	7,260	$156.63	$1,137,133.80	348,502
4/4/2022	Bruce C. Cozadd	CEO	Sell	10,772	$158.33	$1,705,530.76	346,062
2/1/2022	Bruce C. Cozadd	CEO	Sell	6,372	$139.23	$887,173.56
12/2/2021	Mark Douglas Smith	Director	Sell	417	$121.30	$50,582.10
12/1/2021	Bruce C. Cozadd	CEO	Sell	6,748	$122.66	$827,709.68
11/12/2021	Finbar Larkin	SVP	Sell	197	$135.79	$26,750.63
11/11/2021	Kim Sablich	EVP	Sell	2,748	$135.01	$371,007.48
11/1/2021	Bruce C. Cozadd	CEO	Sell	6,556	$134.75	$883,421.00
10/4/2021	Bruce C. Cozadd	CEO	Sell	6,598	$129.87	$856,882.26

How Boeing Disasters Could Impact Nvidia

From Stansberry Research | Ad

How The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart midflight and catching fire. But, according to analyst Dan Ferris, there's something much darker going on here that could threaten Nvidia, the Magnificent 7, and the entire U.S. stock market.

Click here for the full story.

SEC Filings (Institutional Ownership Changes) for Jazz Pharmaceuticals (NASDAQ:JAZZ)

89.14% of Jazz Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Jazz Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
9/5/2024	Sanctuary Advisors LLC	1,950	$0.21M	0.0%	N/A	0.003%
8/26/2024	Teachers Retirement System of The State of Kentucky	107,388	$11.46M	0.1%	-33.5%	0.170%
8/21/2024	Truist Financial Corp	34,322	$3.66M	0.0%	-11.8%	0.054%
8/19/2024	Point72 Asset Management L.P.	182,015	$19.43M	0.1%	-20,323.9%	0.289%
8/16/2024	Systematic Financial Management LP	254,330	$27.15M	0.8%	+5.7%	0.403%
8/16/2024	Creative Planning	3,819	$0.41M	0.0%	+21.7%	0.006%
8/16/2024	Algert Global LLC	5,964	$0.64M	0.0%	N/A	0.009%
8/16/2024	MidWestOne Financial Group Inc.	20,929	$2.23M	0.4%	+62.9%	0.033%
8/15/2024	Susquehanna Fundamental Investments LLC	106,750	$11.39M	0.3%	N/A	0.169%
8/15/2024	Mackenzie Financial Corp	3,299	$0.35M	0.0%	-89.9%	0.005%
8/15/2024	The Manufacturers Life Insurance Company	350,771	$37.44M	0.0%	-0.6%	0.556%
8/15/2024	Millennium Management LLC	450,872	$48.12M	0.0%	+1,808.4%	0.715%
8/15/2024	D. E. Shaw & Co. Inc.	255,871	$27.31M	0.0%	+23.3%	0.406%
8/15/2024	AQR Capital Management LLC	619,100	$66.08M	0.1%	-16.9%	0.982%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	9,966	$1.06M	0.2%	N/A	0.016%
8/14/2024	Squarepoint Ops LLC	3,674	$0.39M	0.0%	-94.3%	0.006%
8/14/2024	Distillate Capital Partners LLC	131,416	$14.03M	0.7%	N/A	0.208%
8/14/2024	Point72 DIFC Ltd	17,077	$1.82M	0.1%	N/A	0.027%
8/14/2024	Marshall Wace LLP	82,959	$8.85M	0.0%	-69.1%	0.132%
8/14/2024	Xponance Inc.	6,774	$0.72M	0.0%	-48.7%	0.011%
8/14/2024	Bank of Montreal Can	68,661	$7.46M	0.0%	-23.3%	0.109%
8/14/2024	Evergreen Capital Management LLC	2,843	$0.30M	0.0%	-83.9%	0.005%
8/14/2024	EverSource Wealth Advisors LLC	273	$30K	0.0%	+55.1%	0.000%
8/14/2024	Itau Unibanco Holding S.A.	272	$29K	0.0%	N/A	0.000%
8/14/2024	ProShare Advisors LLC	6,865	$0.73M	0.0%	-7.7%	0.011%
8/14/2024	Profund Advisors LLC	5,725	$0.61M	0.0%	-21.4%	0.009%
8/13/2024	Rubric Capital Management LP	616,617	$65.81M	1.7%	N/A	0.978%
8/13/2024	Ensign Peak Advisors Inc	28,084	$3M	0.0%	-4.2%	0.045%
8/13/2024	Baupost Group LLC MA	1,274,248	$136M	3.7%	+52.8%	2.021%
8/13/2024	Thrivent Financial for Lutherans	26,193	$2.80M	0.0%	-37.1%	0.042%
8/13/2024	Sei Investments Co.	69,265	$7.39M	0.0%	+61.0%	0.110%
8/13/2024	Pacer Advisors Inc.	1,820,913	$194.35M	0.4%	+40.7%	2.887%
8/13/2024	AE Wealth Management LLC	2,533	$0.27M	0.0%	N/A	0.004%
8/13/2024	Canada Pension Plan Investment Board	160,400	$17.12M	0.0%	-0.7%	0.254%
8/13/2024	Public Employees Retirement Association of Colorado	6,258	$0.67M	0.0%	-3.8%	0.010%
8/12/2024	Intech Investment Management LLC	12,519	$1.34M	0.0%	N/A	0.020%
8/12/2024	XTX Topco Ltd	7,386	$0.79M	0.1%	N/A	0.012%
8/12/2024	Kendall Capital Management	8,449	$0.90M	0.3%	-2.3%	0.013%
8/12/2024	Seven Eight Capital LP	6,432	$0.69M	0.1%	N/A	0.010%
8/12/2024	Hsbc Holdings PLC	45,344	$4.89M	0.0%	+49.6%	0.072%
8/12/2024	Vanguard Personalized Indexing Management LLC	6,239	$0.66M	0.0%	+37.6%	0.010%
8/12/2024	Mercer Global Advisors Inc. ADV	3,485	$0.37M	0.0%	+51.7%	0.006%
8/12/2024	Amalgamated Bank	39,125	$4.18M	0.0%	+4.7%	0.062%
8/10/2024	Mutual of America Capital Management LLC	36,094	$3.85M	0.0%	-3.8%	0.057%
8/9/2024	Renaissance Technologies LLC	1,025,868	$109.49M	0.2%	-12.0%	1.627%
8/9/2024	Dimensional Fund Advisors LP	1,222,198	$130.45M	0.0%	+48.4%	1.938%
8/9/2024	Poehling Capital Management INC.	21,691	$2.32M	0.6%	+3.9%	0.034%
8/9/2024	Thompson Siegel & Walmsley LLC	721,530	$77.01M	1.2%	+30.6%	1.144%
8/8/2024	Envestnet Asset Management Inc.	64,096	$6.84M	0.0%	+1.0%	0.102%
8/8/2024	Oppenheimer Asset Management Inc.	7,846	$0.84M	0.0%	+19.3%	0.012%
8/8/2024	Federated Hermes Inc.	113,017	$12.06M	0.0%	-11.8%	0.179%
8/8/2024	DekaBank Deutsche Girozentrale	83,847	$8.91M	0.0%	-27.3%	0.133%
8/8/2024	Johnson Investment Counsel Inc.	20,730	$2.21M	0.0%	+23.1%	0.033%
8/8/2024	American Century Companies Inc.	92,573	$9.88M	0.0%	-21.2%	0.147%
8/8/2024	State of New Jersey Common Pension Fund D	25,145	$2.68M	0.0%	-25.9%	0.040%
8/7/2024	Headlands Technologies LLC	9,607	$1.03M	0.1%	+96.3%	0.015%
8/7/2024	Royal London Asset Management Ltd.	23,978	$2.56M	0.0%	+5.3%	0.038%
8/7/2024	Texas Permanent School Fund Corp	60,955	$6.51M	0.1%	+10.6%	0.097%
8/7/2024	Fairbanks Capital Management Inc.	27,112	$2.89M	1.9%	+4.5%	0.043%
8/6/2024	LSV Asset Management	2,480,563	$264.75M	0.6%	+4.2%	3.934%
8/6/2024	Ellis Investment Partners LLC	5,925	$0.63M	0.1%	-35.6%	0.009%
8/5/2024	Foundry Partners LLC	3,031	$0.32M	0.0%	N/A	0.005%
8/5/2024	Arizona State Retirement System	16,580	$1.77M	0.0%	+0.8%	0.026%
8/5/2024	Victory Capital Management Inc.	205,492	$21.93M	0.0%	+42.7%	0.326%
8/2/2024	Oregon Public Employees Retirement Fund	13,122	$1.40M	0.0%	-15.8%	0.021%
8/1/2024	Rhumbline Advisers	169,400	$18.08M	0.0%	-8.4%	0.269%
8/1/2024	Natixis Advisors LLC	21,231	$2.27M	0.0%	+10.7%	0.034%
8/1/2024	Waterfront Wealth Inc.	9,411	$1M	0.3%	+2.5%	0.015%
7/31/2024	Van ECK Associates Corp	54,054	$5.77M	0.0%	+4.6%	0.086%
7/31/2024	Commonwealth Equity Services LLC	13,522	$1.44M	0.0%	+2.8%	0.021%
7/30/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	438,211	$46.77M	0.1%	-8.2%	0.695%
7/29/2024	Crossmark Global Holdings Inc.	4,113	$0.44M	0.0%	-19.7%	0.007%
7/29/2024	Principal Financial Group Inc.	209,759	$22.39M	0.0%	-11.7%	0.333%
7/29/2024	Zurcher Kantonalbank Zurich Cantonalbank	10,170	$1.09M	0.0%	-74.3%	0.016%
7/29/2024	Burney Co.	19,823	$2.12M	0.1%	+1.9%	0.031%
7/26/2024	Patriot Financial Group Insurance Agency LLC	3,308	$0.35M	0.1%	-42.2%	0.005%
7/26/2024	AustralianSuper Pty Ltd	95,631	$10.21M	0.1%	+72.8%	0.152%
7/26/2024	Allspring Global Investments Holdings LLC	18,013	$1.92M	0.0%	+12.0%	0.029%
7/26/2024	State of Michigan Retirement System	15,204	$1.62M	0.0%	-14.4%	0.024%
7/26/2024	AlphaCentric Advisors LLC	11,000	$1.17M	0.9%	+29.4%	0.017%
7/26/2024	Bank of New York Mellon Corp	512,813	$54.73M	0.0%	-8.6%	0.813%
7/25/2024	Highland Capital Management LLC	29,990	$3.20M	0.2%	-7.6%	0.048%
7/24/2024	Retirement Systems of Alabama	192,867	$20.59M	0.1%	-0.6%	0.306%
7/24/2024	Louisiana State Employees Retirement System	17,800	$1.90M	0.0%	-1.7%	0.028%
7/23/2024	Fifth Third Wealth Advisors LLC	1,934	$0.21M	0.0%	N/A	0.003%
7/22/2024	Fifth Third Bancorp	3,687	$0.39M	0.0%	-37.1%	0.006%
7/20/2024	China Universal Asset Management Co. Ltd.	7,405	$0.79M	0.1%	-38.3%	0.012%
7/20/2024	Nisa Investment Advisors LLC	249	$27K	0.0%	-98.3%	0.000%
7/20/2024	Hennion & Walsh Asset Management Inc.	29,447	$3.14M	0.2%	+16.6%	0.047%
7/19/2024	Greylin Investment Management Inc	9,050	$0.97M	0.2%	N/A	0.014%
7/19/2024	Raymond James & Associates	47,318	$5.05M	0.0%	-11.5%	0.075%
7/19/2024	Sumitomo Mitsui Trust Holdings Inc.	18,119	$1.93M	0.0%	-88.6%	0.029%
7/19/2024	CFM Wealth Partners LLC	2,624	$0.28M	0.1%	-37.3%	0.004%
7/19/2024	Gladius Capital Management LP	309	$33K	0.0%	N/A	0.000%
7/18/2024	Blue Trust Inc.	1,307	$0.14M	0.0%	+24.5%	0.002%
7/18/2024	Ellsworth Advisors LLC	37,181	$3.97M	1.1%	+3.9%	0.059%
7/18/2024	Assenagon Asset Management S.A.	17,017	$1.82M	0.0%	-8.3%	0.027%
7/18/2024	Fiduciary Financial Group LLC	2,277	$0.24M	0.1%	N/A	0.004%
7/18/2024	Swedbank AB	1,001,932	$106.94M	0.1%	N/A	1.589%
7/16/2024	Envestnet Portfolio Solutions Inc.	2,753	$0.29M	0.0%	+13.9%	0.004%

Data available starting January 2016

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $110.22

$109.31

$110.78

50 Day Range

MA: $110.21

$100.57

$116.37

52 Week Range

Now: $110.22

$99.06

$137.38

Volume

121,080 shs

Average Volume

684,046 shs

Market Capitalization

$6.95 billion

P/E Ratio

22.73

Dividend Yield

N/A

Beta

0.57

Who are the company insiders with the largest holdings of Jazz Pharmaceuticals?: Jazz Pharmaceuticals' top insider shareholders include:
Bruce C Cozadd (CEO)
Neena M Patil (EVP)
Robert Iannone (EVP)
Renee D Gala (CFO)
Kim Sablich (EVP)
Philip L Johnson (CFO)
Finbar Larkin (SVP)
Kenneth W O'keefe (Director)
Patrick G Enright (Director)
Mary Elizabeth Henderson (SVP)
Samantha Pearce (SVP)
Rick E Winningham (Director)
Patricia Carr (CAO)
Mark Douglas Smith (Director)
Jennifer E Cook (Director)
Learn More about top insider investors at Jazz Pharmaceuticals.
Who are the major institutional investors of Jazz Pharmaceuticals?: Jazz Pharmaceuticals' top institutional investors include:
LSV Asset Management — 3.93%
Pacer Advisors Inc. — 2.89%
Baupost Group LLC MA — 2.02%
Dimensional Fund Advisors LP — 1.94%
Renaissance Technologies LLC — 1.63%
Swedbank AB — 1.59%
Learn More about top institutional investors of Jazz Pharmaceuticals stock.
Which major investors are selling Jazz Pharmaceuticals stock?: Within the previous quarter, JAZZ stock was sold by these institutional investors:
Marshall Wace LLP
Sumitomo Mitsui Trust Holdings Inc.
Renaissance Technologies LLC
AQR Capital Management LLC
Squarepoint Ops LLC
Teachers Retirement System of The State of Kentucky
Bank of New York Mellon Corp
BNP PARIBAS ASSET MANAGEMENT Holding S.A.
In the previous year, company insiders that have sold Jazz Pharmaceuticals company stock include:
Bruce C Cozadd (CEO)
Neena M Patil (EVP)
Robert Iannone (EVP)
Renee D Gala (CFO)
Learn More investors selling Jazz Pharmaceuticals stock.
Which major investors are buying Jazz Pharmaceuticals stock?: During the last quarter, JAZZ stock was acquired by institutional investors including:
Swedbank AB
Rubric Capital Management LP
Pacer Advisors Inc.
Baupost Group LLC MA
Millennium Management LLC
Dimensional Fund Advisors LP
Point72 Asset Management L.P.
Thompson Siegel & Walmsley LLC